Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.

Ulrich Keilholz, Jérôme Fayette, Andreas Dietz et al.|Journal of Clinical Oncology|2018

Cited by 5